9336
Z.-Y. Yan et al. / Tetrahedron 61 (2005) 9331–9337
2815, 1599, 1504, 1454, 1116; EI-MS m/z 244 (MC), 226,
214, 201, 159, 130, 77; HRMS (EI) found [MKN2H]CZ
215.1179, C13H15N2O requires 215.1179.
4.3.12.
(1-[4-Nitro-phenyl]-1H-[1,2,3]triazol-4-yl-
methyl)-morpholine (4l). Solid, mp 195–197 8C; 1H
NMR (300 MHz, CDCl3) d 8.43 (d, JZ8.7 Hz, 2H), 8.10
(s, 1H), 8.00 (d, JZ8.7 Hz, 2H), 3.74–3.80 (m, 6H), 2.61 (br
s, 4H); 13C NMR (75 MHz, CDCl3) d 147.1, 145.9, 141.1,
125.5, 120.7, 120.3, 66.7, 53.5 (2C); IR (KBr, cmK1) 1523,
1343, 1113, 856; EI-MS m/z 289 (MC), 246, 204, 129, 86;
HRMS (EI) found [M–N2H]CZ260.1028, C13H14N3O3
requires 260.1030.
4.3.6. 1,4-Bis-(1-phenyl-1H-[1,2,3]triazol-4-ylmethyl)-
piperazine (4f). Solid, mp 158–160 8C; 1H NMR
(300 MHz, CDCl3) d 8.12 (s, 2H), 7.71 (d, JZ7.8 Hz,
4H), 7.50 (t, JZ7.8, 7.2 Hz, 4H), 7.39 (t, JZ7.2 Hz, 2H),
3.90 (s, 4H), 2.83 (br s, 8H); 13C NMR (75 MHz, CDCl3) d
137.1, 130.0, 129.1, 122.1, 120.9, 120.7, 52.9, 52.1; IR
(KBr, cmK1) 1598, 1503, 1461, 1045; FAB-MS m/z 401.3
[MC1]C; HRMS (EI) found [M]CZ400.2117, C22H24N8
requires 400.2118.
4.3.13. (1-[4-Methyl-phenyl]-1H-[1,2,3]triazol-4-yl-
methyl)-piperidine (4m). Solid, mp 109–111 8C; 1H
NMR (300 MHz, CDCl3) d 7.90 (s, 1H), 7.58 (d, JZ
7.8 Hz, 2H), 7.27 (d, JZ7.8 Hz, 1H), 3.68 (s, 2H), 2.46 (br
s, 4H), 2.38 (s, 3H), 1.56 (br s, 4H), 1.41 (br s, 2H); 13C
NMR (75 MHz, CDCl3) d 145.3, 138.5, 134.7, 130.1, 120.7,
120.2, 54.2, 54.0, 25.7, 24.0, 21.0; IR (KBr, cmK1) 2938,
1528, 1113; EI-MS m/z 256 (MC), 173, 91, 84; HRMS (EI)
found [M]CZ256.1684, C15H20N4 requires 256.1682.
4.3.7. Bis-(1-[4-chloro-phenyl]-1H-[1,2,3]triazol-4-yl-
methyl)-butylamine (4g). Solid, mp 88–90 8C; H NMR
1
(300 MHz, CDCl3) d 8.03 (s, 2H), 7.61 (m, 4H), 7.37 (m,
4H), 3.79 (s, 4H), 2.50 (t, JZ7.2 Hz, 2H), 1.54 (m, 2H),
1.24 (m, 2H), 0.82 (m, 3H); 13C NMR (75 MHz, CDCl3) d
145.3, 135.2, 134.0, 129.6, 126.3, 121.2, 121.0, 53.3, 47.4,
29.2, 20.2, 13.8; IR (KBr, cmK1) 2956, 2930, 1501, 1226,
1096, 1043; FAB-MS m/z 456.2 [M] C; HRMS (EI) found
[M]CZ455.1389, C22H23N7Cl2 requires 455.1387.
4.3.14. (1-[4-Methyl-phenyl]-1H-[1,2,3]triazol-4-yl-
methyl)-morpholine (4n). Solid, mp 102–103 8C; 1H
NMR (300 MHz, CDCl3) d 7.89 (s, 1H), 7.59 (d, JZ
8.1 Hz, 2H), 7.30 (d, JZ8.1 Hz, 2H), 3.73 (s, 2H), 3.72
(t, JZ4.5 Hz, 4H), 2.56 (br s, 4H), 2.41 (s, 3H); 13C NMR
(75 MHz, CDCl3) d 145.0, 139.0, 135.0, 130.5, 121.0,
120.6, 67.1, 53.9, 53.7, 21.3; IR (KBr, cmK1) 1521, 1449,
1113; EI-MS m/z 258 (MC), 240, 228, 215, 173, 144, 91;
HRMS (EI) found [M–N2H]CZ229.1378, C14H17N2O
requires 229.1335.
4.3.8. (1-Phenyl)-1H-[1,2,3]triazol-4-ylmethyl)-phenyl-
amine (4h). Solid, mp 138–140 8C; H NMR (300 MHz,
1
CDCl3) d 7.88 (s, 1H), 7.69 (d, JZ8.1 Hz, 2H), 7.53–7.40
(m, 3H), 7.26–7.18 (m, 2H), 6.78–6.70 (m, 3H), 4.55 (s,
2H); 4.32 (br s, 1H); 13C NMR (75 MHz, CDCl3) d 147.4,
147.0, 137.0, 129.7, 129.3, 128.7, 120.4, 119.8, 118.1,
113.1, 39.9; IR (KBr, cmK1) 1598, 1462, 1320, 1105;
EI-MS m/z 250 (MC), 221, 130, 77; HRMS (EI) found
[M]CZ250.1210, C15H14N4 requires 250.1213.
4.3.15. (1-[4-Methyl-phenyl]-1H-[1,2,3]triazol-4-yl-
methyl)-diethylamine (4o). Oil; 1H NMR (300 MHz,
CDCl3) d 7.91 (s, 1H), 7.57 (d, JZ8.1 Hz, 2H), 7.26 (d,
JZ8.1 Hz, 2H), 3.85 (s, 2H), 2.59 (q, 4H), 2.37 (s, 3H), 1.09
(t, JZ7.2 Hz, 6H); 13C NMR (75 MHz, CDCl3) d 145.6,
138.9, 135.1, 130.4, 121.0, 120.5, 47.9, 47.0, 21.3, 11.9; IR
(KBr, cmK1) 2970, 1520, 1459, 1226, 1042; EI-MS m/z 244
(MC), 229, 215, 201, 187, 173, 144, 91, 72; HRMS (EI)
found [M]CZ244.1678, C14H20N4 requires 244.1682.
4.3.9.
(1-[4-Chloro-phenyl]-1H-[1,2,3]triazol-4-yl-
1
methyl)-piperidine (4i). Solid, mp 120–122 8C; H NMR
(300 MHz, CDCl3) d 7.93 (s, 1H), 7.70 (d, JZ8.7 Hz, 2H),
7.41 (d, JZ8.7 Hz, 2H), 3.72 (s, 2H), 2.50 (br s, 4H), 1.60
(m, 4H), 1.45 (m, 2H); 13C NMR (75 MHz, CDCl3) d 145.6,
135.5, 134.2, 129.8, 121.4, 120.7, 54.3, 53.9, 25.7, 23.9; IR
(KBr, cmK1) 2936, 1502, 1440, 1098, 1048; EI-MS m/z 276
(MC), 247, 193, 84; HRMS (EI) found [M]CZ276.1136,
C14H17N4Cl requires 276.1136.
4.3.16. (1-Benzyl-1H-[1,2,3]triazol-4-ylmethyl)-piperi-
dine (4p). Solid, mp 97–99 8C; 1H NMR (300 MHz,
CDCl3) d 7.41 (s, 1H), 7.38–7.34 (m, 2H), 7.28 (m, 3H),
5.51 (s, 2H), 3.62 (s, 2H), 2.43 (br s, 4H), 1.58–1.53 (m,
4H), 1.43–1.41 (d, 2H); 13C NMR (75 MHz, CDCl3) d
145.1, 134.6, 129.0, 128.6, 128.0, 122.4, 54.2 (2C), 54.0,
25.7, 24.0; IR (KBr, cmK1) 2931, 2771, 1445, 1306, 1050;
EI-MS m/z 256 (MC), 173, 91, 84; HRMS (EI) found
[M]CZ256.1682, C15H20N4 requires 256.1682.
4.3.10. (1-[4-Chloro-phenyl]-1H-[1,2,3]triazol-4-yl-
methyl)-morpholine (4j). Solid, mp 119–121 8C; 1H
NMR (300 MHz, CDCl3) d 7.95 (s, 1H), 7.70 (d, JZ
8.7 Hz, 2H), 7.50 (d, JZ8.7 Hz, 2H), 3.72–3.75 (m, 6H),
2.58 (br s, 4H); 13C NMR (75 MHz, CDCl3) d 145.4, 135.7,
134.7, 130.1, 121.8, 121.0, 67.0, 53.8, 53.7; IR (KBr, cmK1
)
2925, 1502, 1115; EI-MS m/z 278 (MC), 235, 193, 164;
HRMS (EI) found [M–N2H]CZ249.0786, C13H14N2ClO
requires 249.0789.
4.3.17. (1-Phenoxyethyl-1H-[1,2,3]triazol-4-ylmethyl)-
piperidine (4q). Solid, mp 103–104 8C; 1H NMR
(300 MHz, CDCl3) d 7.71 (s, 1H), 7.28 (t, JZ8.4, 7.5 Hz,
2H), 6.97 (t, JZ8.4, 7.5 Hz, 1H), 6.86 (d, JZ9.0 Hz, 2H),
4.74 (t, JZ4.8 Hz, 2H), 4.35 (t, JZ4.8 Hz, 2H), 3.66 (s,
2H), 2.45 (br s, 4H), 1.62–1.54 (m, 4H), 1.45–1.41 (m, 2H);
13C NMR (75 MHz, CDCl3) d 157.7, 144.6, 129.5, 123.8,
121.5, 114.4, 66.2, 54.1, 53.9, 49.6, 25.7, 24.0; IR (KBr,
cmK1) 2930, 2770, 1596, 1497, 1460, 1252, 1118, 1047;
EI-MS m/z 286 (MC), 203, 84; HRMS (EI) found [M]CZ
286.1785, C16H22N4O requires 286.1788.
4.3.11.
(1-[4-Nitro-phenyl]-1H-[1,2,3]triazol-4-yl-
1
methyl)-piperidine (4k). Solid, mp 109–111 8C; H NMR
(300 MHz, CDCl3) d 8.42 (d, JZ8.7 Hz, 2H), 8.09 (s, 1H),
8.00 (d, JZ8.7 Hz, 2H), 3.75 (s, 2H), 2.51 (br s, 4H), 1.61
(m, 4H), 1.46 (m, 2H); 13C NMR (75 MHz, CDCl3) d 147.0,
146.8, 141.2, 125.5, 120.5, 120.2, 54.4, 53.9, 25.8, 24.0; IR
(KBr, cmK1) 2938, 1600, 1528, 1507, 1447, 1343, 1111,
1042, 909; EI-MS m/z 287 (MC), 204, 129, 84; HRMS (EI)
found [M]CZ287.1380, C14H17N5O2 requires 287.1377.